<?xml version='1.0' encoding='UTF-8'?>
<search_results><query id="7263">hospital acquired pneumonia</query><engine status="OK" timestamp="2014-04-25 12:09:41" name="SpringerLink" id="FW14-e013"/><snippets><snippet id="FW14-e013-7263-01"><link cache="FW14-topics-docs/e013/7263_01.html" timestamp="2014-04-25 12:09:41">http://link.springer.com/referenceworkentry/10.1007/978-3-642-00418-6_1708</link><title>Hospital-Acquired Pneumonia</title><description>Encyclopedia of Intensive Care Medicine (2012)</description></snippet><snippet id="FW14-e013-7263-02"><link cache="FW14-topics-docs/e013/7263_02.html" timestamp="2014-04-25 12:10:25">http://link.springer.com/referenceworkentry/10.1007/978-3-642-00418-6_1710</link><title>Hospital-Acquired Pneumonia = Nosocomial Pneumonia</title><description>Encyclopedia of Intensive Care Medicine (2012)</description></snippet><snippet id="FW14-e013-7263-03"><link cache="FW14-topics-docs/e013/7263_03.html" timestamp="2014-04-25 12:10:54">http://link.springer.com/article/10.2165/00128413-200716180-00038</link><title>Telavancin promising for hospital-acquired pneumonia</title><description>Inpharma Weekly (2007)</description></snippet><snippet id="FW14-e013-7263-04"><link cache="FW14-topics-docs/e013/7263_04.html" timestamp="2014-04-25 12:11:21">http://link.springer.com/article/10.2165/00151234-200504930-00033</link><title>Guidelines decrease mortality from severe hospital-acquired pneumonia</title><description>PharmacoEconomics &amp; Outcomes News (2005)</description></snippet><snippet id="FW14-e013-7263-05"><link cache="FW14-topics-docs/e013/7263_05.html" timestamp="2014-04-25 12:12:12">http://link.springer.com/article/10.1186/cc9603</link><title>Hospital-acquired pneumonia is associated with deficient γc-cytokine gene expression</title><description>M White, R McManus, T Ryan in Critical Care (2011)</description></snippet><snippet id="FW14-e013-7263-06"><link cache="FW14-topics-docs/e013/7263_06.html" timestamp="2014-04-25 12:12:41">http://link.springer.com/article/10.1007/BF03275052</link><title>Cefepime preferable in hospital-acquired pneumonia</title><description>PharmacoEconomics &amp; Outcomes News Weekly (1999)</description></snippet><snippet id="FW14-e013-7263-07"><link cache="FW14-topics-docs/e013/7263_07.html" timestamp="2014-04-25 12:13:20">http://link.springer.com/article/10.1186/cc7474</link><title>Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies</title><description>E Rubinstein, GR Corey, HW Boucher, MS Niederman, A Shorr, A Torres… in Critical Care (2009)</description></snippet><snippet id="FW14-e013-7263-08"><link cache="FW14-topics-docs/e013/7263_08.html" timestamp="2014-04-25 12:14:08">http://link.springer.com/article/10.2165/00128413-199912010-00009</link><title>Cefepime preferable in hospital-acquired pneumonia</title><description>Inpharma Weekly (1999)</description></snippet><snippet id="FW14-e013-7263-09"><link cache="FW14-topics-docs/e013/7263_09.html" timestamp="2014-04-25 12:14:38">http://link.springer.com/article/10.2165/00128413-200816640-00032</link><title>Telavancin ATTAINs benefit in hospital-acquired pneumonia</title><description>Inpharma Weekly (2008)</description></snippet><snippet id="FW14-e013-7263-10"><link cache="FW14-topics-docs/e013/7263_10.html" timestamp="2014-04-25 12:15:25">http://link.springer.com/article/10.1007/s10156-004-0364-9</link><title>Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia</title><description>Niro Okimoto, Kenji Yamato, Yoshihiro Honda… in Journal of Infection and Chemotherapy (2005)</description></snippet></snippets></search_results>